{"disease":{"id":"lymphoma-t-cell","name":"lymphoma t cell"},"drugs":{"marketed":[{"drug_id":"lorlatinib-with-chemotherapy-2","indication_name":"Anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) with brain metastases","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorlatinib with chemotherapy 2","generic_name":"lorlatinib-with-chemotherapy-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ALK","drug_class":"ALK inhibitor","quality_score":40,"revenue":"798","mechanism":""},{"drug_id":"alectinib","indication_name":"Anaplastic lymphoma kinase positive anaplastic large cell lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alecensa","generic_name":"alectinib","company_name":"Hoffmann-La Roche","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor","quality_score":79,"revenue":"700","mechanism":"Alecensa blocks the activity of the ALK protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"brigatinib","indication_name":"Advanced/recurrent anaplasticlymphoma kinase (ALK)-positive non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alunbrig","generic_name":"brigatinib","company_name":"Takeda","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Alunbrig works by blocking the activity of the ALK tyrosine kinase receptor, which is involved in the growth and spread of cancer cells."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT05907447","title":"A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03869619","title":"REal World Data in LYmphoma and Survival in Adults","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06339255","title":"Italian Observational Study on CAR-T Therapy for Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":5300,"lead_sponsor_name":"Paolo Corradini","has_results":false},{"nct_id":"NCT06549361","title":"A Retrospective Study on Extranodal DLBCL","phase":"","overall_status":"COMPLETED","enrollment_count":5023,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT06573099","title":"A Real-World Study on Extranodal Lymphoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT00626496","title":"Family Study of Lymphoproliferative Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03646422","title":"AEDV Registry of Primary Cutaneous Lymphoma","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Fundación Academia Española de Dermatología","has_results":false},{"nct_id":"NCT05334069","title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT03904134","title":"Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)","phase":"NA","overall_status":"COMPLETED","enrollment_count":1753,"lead_sponsor_name":"Center for International Blood and Marrow Transplant Research","has_results":false},{"nct_id":"NCT00700258","title":"Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]","phase":"","overall_status":"COMPLETED","enrollment_count":1520,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03050268","title":"Familial Investigations of Childhood Cancer Predisposition","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01676805","title":"Tissue Collection for Studies of Lymph Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1295,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01087333","title":"Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":1263,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05978141","title":"A Registry for People With T-cell Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03907488","title":"Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":994,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02793583","title":"Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":710,"lead_sponsor_name":"TG Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03289182","title":"An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)","phase":"","overall_status":"COMPLETED","enrollment_count":701,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT01804686","title":"A Long-term Extension Study of PCI-32765 (Ibrutinib)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT02972840","title":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":635,"lead_sponsor_name":"Acerta Pharma BV","has_results":false},{"nct_id":"NCT04858568","title":"Immune Responses to COVID-19 Vaccination in Lymphoma Patients","phase":"","overall_status":"COMPLETED","enrollment_count":592,"lead_sponsor_name":"University Hospital Southampton NHS Foundation Trust","has_results":false},{"nct_id":"NCT01787409","title":"Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":565,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05934084","title":"Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors","phase":"NA","overall_status":"RECRUITING","enrollment_count":552,"lead_sponsor_name":"Fondazione Italiana Linfomi - ETS","has_results":false},{"nct_id":"NCT02568267","title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":534,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT02847130","title":"Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology","phase":"","overall_status":"COMPLETED","enrollment_count":530,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT03425591","title":"A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":508,"lead_sponsor_name":"Janssen-Cilag Ltd.","has_results":false},{"nct_id":"NCT03207789","title":"T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Grupo de Estudos Multicentricos em Onco-Hematologia","has_results":false},{"nct_id":"NCT03375619","title":"Long-term Follow-up Study of Patients Receiving CAR-T Cells","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Medical College of Wisconsin","has_results":false},{"nct_id":"NCT02682667","title":"Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01777152","title":"ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":452,"lead_sponsor_name":"Seagen Inc.","has_results":true},{"nct_id":"NCT00877006","title":"Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":447,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D, Inc.","has_results":true},{"nct_id":"NCT04384484","title":"Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":440,"lead_sponsor_name":"ADC Therapeutics S.A.","has_results":false},{"nct_id":"NCT04799275","title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","phase":"PHASE2, PHASE3","overall_status":"SUSPENDED","enrollment_count":422,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04952974","title":"B-cell Chronic Lymphoid Malignancies Markers","phase":"","overall_status":"UNKNOWN","enrollment_count":420,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT06564038","title":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":408,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01897571","title":"Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Epizyme, Inc.","has_results":true},{"nct_id":"NCT05108298","title":"Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials","phase":"NA","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Eastern Cooperative Oncology Group","has_results":false},{"nct_id":"NCT05633615","title":"Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":396,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT02631044","title":"Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":387,"lead_sponsor_name":"Juno Therapeutics, a Subsidiary of Celgene","has_results":false},{"nct_id":"NCT03984448","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":363,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04115631","title":"A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":360,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT04537871","title":"Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":350,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT01856192","title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":349,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00001337","title":"Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":348,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00303719","title":"Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":342,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT01582776","title":"Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":317,"lead_sponsor_name":"The Lymphoma Academic Research Organisation","has_results":false},{"nct_id":"NCT02348216","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":307,"lead_sponsor_name":"Kite, A Gilead Company","has_results":true},{"nct_id":"NCT05466318","title":"ChiCGB vs BEAM in High-risk or R/R Lymphomas","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":306,"lead_sponsor_name":"Sichuan University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}